

Differential CpG methylation at *Nnat* in the early establishment of beta cell heterogeneity

Vanessa Yu, Fiona Yong, Angellica Marta, ... Yusuf Ali ... Steven J. Millership

• Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK
• Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Republic of Singapore
• Nutrition, Metabolism and Health Programme & Centre for Microbiome Medicine, Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Republic of Singapore

Introduction




Figure 1. Neuronatin (*Nnat*) is an imprinted gene in humans and mice, critical for glucose-stimulated insulin secretion in vivo [1]. Its expression is regulated by CpG methylation. Pancreatic beta cells are functionally heterogeneous, with distinct subpopulations that coordinate islet-wide Ca^{2+} dynamics.

This paper aims to determine whether *Nnat* marks a specific subpopulation of functional beta cells and to explore how CpG methylation and other epigenetic pathways contribute to their formation and maintenance.

METHODS

Single cell RNA-seq islet data were downloaded from Gene Expression Omnibus database and filtered according to the respective published work and hypervariability of gene expression was assessed by variance analysis to avoid artefacts resulting from technical dropouts. Extraction of islet clusters identified two distinct subpopulations of beta cells where cells with *Nnat* expression <3 was dedicated as *Nnat*⁻ and >3 as *Nnat*⁺. Mice with *Nnat*-driven enhanced GFP under the control of the *Nnat* enhancer/promoter regions were purchased from the Mutant Mouse Resource and Research Centre while mice with deletion of the DNMT3A from the pancreatic progenitor stage were obtained from The Jackson Laboratory. From the mice, pancreatic islets expressing *Nnat*-eGFP were isolated and Ca^{2+} imaging of whole islets was performed.

RESULTS




Figure 2. Distribution of *Nnat* expression among beta cell clusters, along with the expression range used in defining *Nnat*⁺ beta cells (highlighted by the red rectangle). 2 beta cell populations with distinct levels of *Nnat* expression were identified indicating the heterogeneous expression of *Nnat* across the islet [2,3]




Figure 3. Quantification of *Nnat*⁺ beta cells, expressed as *Nnat*/INS co-positive cells as a percentage of total INS-positive cells. Scale bar, 50µm ($n=8$ mice per genotype, unpaired Student's t test, $**p<0.01$). Nuclei are visualised with DAPI

Nnat staining in control mice at P6 demonstrated expression in a subpopulation of beta cells, whereas deletion of DNMT3A resulted in a loss of this heterogeneous expression across the islet. *Nnat* mRNA was differentially expressed in a discrete beta cell population in a DNMT3A-dependent manner.

Figure 4. Insulin content assessed in *Nnat*⁺ and *Nnat*⁻ beta cells (* $p<0.05$, $n=7$ m FACS-purified populations from individual mouse islet preparations, Wilcoxon matched-pairs signed rank test). FACS-sorted primary *Nnat*⁺ beta cells had a significantly higher insulin content than *Nnat*⁻ cells.





Figure 5. Representative Cartesian map of beta cells with colour-coded lines connecting cells according to the strength of coactivation (colour-coded *R* values from 0 to 1, blue to red).

Beta cells are represented by differently coloured nodes depending on their coactivity with the other beta cells, where black nodes indicate coactivity with $\geq 80\%$ of the remaining beta cells, while grey, white and orange nodes represent coactivity with $\geq 60\%$, $\geq 40\%$ and $<40\%$, respectively. Nodes circled with a solid black line indicate *Nnat*⁺ cells.




Figure 6. The wild-type 'hub' cells were significantly more connected than *Nnat*-deficient 'hub' cells. The proportion of highly-connected 'hubs' to 'followers' were significantly decreased in both wild type and *Nnat* deficient islets under high glucose ($p<0.001$). There were no significant differences in the proportion of 'hub'/follower cells between the wild type and *Nnat* deficient islets under high glucose conditions ($p=0.36$).

DISCUSSION

CpG methylation at the *Nnat* promoter plays a crucial role in early beta cell maturation by restricting its expression to a specialized subpopulation of beta cells. This process establishes functional heterogeneity within beta cells, essential for distinct roles in insulin production and glucose metabolism [1,4]. NNAT⁺ beta cells are enriched for pathways related to translation initiation and oxidative phosphorylation, emphasizing their specialization in insulin synthesis rather than glucose sensing.

The loss or reduction of NNAT⁺ beta cells correlates with impaired glucose-stimulated insulin secretion, a hallmark of Type 2 diabetes. Altered CpG methylation at the *Nnat* locus may contribute to the disruption of beta cell hierarchy and functionality in diabetic states. These findings highlight the therapeutic potential of targeting CpG methylation and other epigenetic modifications to preserve or restore beta cell function [5]. Such strategies could provide novel approaches for beta cell replacement, regeneration, or modulation in diabetes treatment.

CONCLUSION

CpG methylation plays a crucial role in early beta cell developmental maturation, restricting *Nnat* expression in specific beta cells during early maturation. This leads to reduced glucose-stimulated insulin secretion, contributing to the development of Type 2 diabetes [6]. Retention of *Nnat*⁺ beta cells in adulthood is also indicative of its distinct functional role in the mature islets, contributing to a heterogeneous population of beta cells [6]. Chemical modification of the epigenome through CpG methylation may provide an attractive therapeutic angle for both beta cell replacement or regeneration and modulation of beta cell function and cell-cell connectivity in type 2 diabetes.

REFERENCES

1. Parveen N, Wang JK, Bhattacharya S, et al. (2023) Diabetes 72:575-589
2. Johnston NR, Mitchell RK, Haythorne E, et al. (2016) Cell Metab 24:389-401
3. Salem V, Silva LD, Suba K, et al. (2019) Nat Metab 1:615-629
4. Chabosseau P, Rutter GA, Millership SJ (2021) Int J Mol Sci 22:1000
5. Dhawan S, Tschen SI, Zeng C, et al. (2015) J Clin Invest 125:2851-2860
6. Dror E, Fagnocchi L, Wegert V, et al. (2023) Cell Metab 35:821-836.e7

ACKNOWLEDGEMENTS

This work is supported by LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility, MRC LMS Genomics Facility and the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE-T2EP30221-0003).